Compare NSSC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | NNNN |
|---|---|---|
| Founded | 1969 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1994 | N/A |
| Metric | NSSC | NNNN |
|---|---|---|
| Price | $38.24 | $23.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.17 | N/A |
| AVG Volume (30 Days) | ★ 849.8K | 26.3K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | N/A |
| P/E Ratio | ★ $54.00 | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.63 | $5.91 |
| 52 Week High | $47.61 | $55.65 |
| Indicator | NSSC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 52.80 |
| Support Level | $37.41 | $19.53 |
| Resistance Level | $44.43 | $30.70 |
| Average True Range (ATR) | 1.50 | 1.97 |
| MACD | -0.49 | 0.41 |
| Stochastic Oscillator | 3.46 | 84.48 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.